DE60012980T2 - Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen - Google Patents

Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen Download PDF

Info

Publication number
DE60012980T2
DE60012980T2 DE60012980T DE60012980T DE60012980T2 DE 60012980 T2 DE60012980 T2 DE 60012980T2 DE 60012980 T DE60012980 T DE 60012980T DE 60012980 T DE60012980 T DE 60012980T DE 60012980 T2 DE60012980 T2 DE 60012980T2
Authority
DE
Germany
Prior art keywords
scfv
protein
library
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012980T
Other languages
German (de)
English (en)
Other versions
DE60012980D1 (de
Inventor
Adrian Auf Der Maur
Alcide Barberis
Dominik Escher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech AG filed Critical Esbatech AG
Application granted granted Critical
Publication of DE60012980D1 publication Critical patent/DE60012980D1/de
Publication of DE60012980T2 publication Critical patent/DE60012980T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Stored Programmes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Catalysts (AREA)
DE60012980T 1999-12-28 2000-12-18 Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen Expired - Lifetime DE60012980T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IB9902054 1999-12-28
WOPCT/IB99/02054 1999-12-28
WOPCT/IB00/00218 2000-03-01
IBPCT/IB00/00218 2000-03-01
PCT/IB2000/001892 WO2001048017A1 (en) 1999-12-28 2000-12-18 Intrabodies with defined framework that is stable in a reducing environment and applications thereof

Publications (2)

Publication Number Publication Date
DE60012980D1 DE60012980D1 (de) 2004-09-16
DE60012980T2 true DE60012980T2 (de) 2005-08-18

Family

ID=26318608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60012980T Expired - Lifetime DE60012980T2 (de) 1999-12-28 2000-12-18 Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen

Country Status (10)

Country Link
US (3) US7258986B2 (https=)
EP (3) EP1242457B1 (https=)
JP (4) JP4698109B2 (https=)
AT (1) ATE273323T1 (https=)
AU (1) AU768827B2 (https=)
CA (1) CA2396534C (https=)
DE (1) DE60012980T2 (https=)
DK (1) DK1242457T3 (https=)
ES (1) ES2225269T3 (https=)
WO (1) WO2001048017A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028502A1 (en) * 1997-11-28 1999-06-10 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
IT1317922B1 (it) * 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast
US20050037420A1 (en) * 2001-09-14 2005-02-17 Mei-Yun Zhang Immunoglobulin having particular framework scaffold and methods of making and using
WO2003077945A1 (en) * 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
AU2012211497C1 (en) * 2002-05-22 2021-07-29 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
AU2013203285B2 (en) * 2002-05-22 2015-04-23 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
JP2006508638A (ja) 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
AU2015202410B2 (en) * 2002-05-22 2017-09-14 Novartis Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CA2523912A1 (en) * 2003-04-30 2004-11-11 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
KR100635370B1 (ko) 2005-03-04 2006-10-17 주식회사 녹십자홀딩스 ＳｃＦｖ 형태의 항체 라이브러리를 제작하기 위한 항체 ＳｃＦｖ 발현벡터
JP5171611B2 (ja) * 2005-03-25 2013-03-27 ナショナル リサーチ カウンシル オブ カナダ 可溶性ポリペプチドの単離方法
FR2883886B1 (fr) * 2005-04-05 2010-12-03 Biomethodes Methode d'obtention de variants solubles ou mieux exprimes d'une proteine d'interet
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
JP4938263B2 (ja) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
EP2360473A1 (en) * 2005-08-22 2011-08-24 Cornell Research Foundation Compositions and methods for analyzing protein interactions
BRPI0710971A2 (pt) * 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
ES2820837T3 (es) * 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial
US8722584B2 (en) * 2007-01-12 2014-05-13 Cornell University Genetic selection for protein folding and solubility in the bacterial periplasm
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
EP2134841B9 (en) * 2007-03-15 2014-06-11 Inserm Methods for producing active scfv antibodies and libraries therefor
DK2164514T3 (en) * 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
EP2164961B1 (en) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR102050040B1 (ko) * 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
PL3628686T3 (pl) 2008-06-25 2022-02-28 Novartis Ag Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP2016506974A (ja) * 2013-02-15 2016-03-07 エスバテック − ア ノバルティスカンパニー エルエルシー Ｃｄｒグラフトのためのアクセプターフレームワーク
CA2896174A1 (en) 2013-02-20 2014-08-28 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
US20170219596A1 (en) * 2014-07-14 2017-08-03 The Regents Of The University Of California A protein tagging system for in vivo single molecule imaging and control of gene transcription
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3191592A1 (en) 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
WO2016089883A1 (en) 2014-12-01 2016-06-09 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US10738118B2 (en) 2015-05-29 2020-08-11 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
WO2023229535A1 (en) 2022-05-27 2023-11-30 Engine Biosciences Pte. Ltd. Bet polypeptide therapeutic agents for generating synthetic lethality in tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
FR2627508B1 (fr) 1988-02-22 1990-10-05 Eurolysine Procede pour l'integration d'un gene choisi sur le chromosome d'une bacterie et bacterie obtenue par ledit procede
FR2648713B1 (fr) 1989-06-26 1994-06-10 Commissariat Energie Atomique Proteines hybrides entre une enzyme extracytoplasmique et une autre proteine, leur procede de preparation, ainsi que leur application comme agent de diagnostic
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
JPH05105700A (ja) 1991-07-15 1993-04-27 Tosoh Corp 酵母に対する血清又は抗体、それらの調製方法及びそれらの使用方法
JPH0597704A (ja) 1991-10-07 1993-04-20 Hisashi Ishihara 新抗体ワクチン製造技法
JPH0630778A (ja) 1992-07-17 1994-02-08 Tosoh Corp ピキア酵母により抗体を製造するためのベクタ−、該ベクタ−で形質転換されたピキア酵母及び形質転換ピキア酵母を培養することを特徴とする抗体の製造方法
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
JPH0920798A (ja) 1995-07-11 1997-01-21 Asahi Chem Ind Co Ltd ヒト抗ＨＢｓ抗体
DK0877752T3 (da) * 1996-01-23 2003-09-15 Univ Leland Stanford Junior Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20030017149A1 (en) * 1996-10-10 2003-01-23 Hoeffler James P. Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
JP4041913B2 (ja) 1997-02-13 2008-02-06 独立行政法人農業・食品産業技術総合研究機構 抗腫瘍タンパク質およびその遺伝子
JPH11174A (ja) 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
WO1999028502A1 (en) * 1997-11-28 1999-06-10 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcription in vivo
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins

Also Published As

Publication number Publication date
US7258986B2 (en) 2007-08-21
JP5783703B2 (ja) 2015-09-24
WO2001048017A1 (en) 2001-07-05
JP4698109B2 (ja) 2011-06-08
US20030096306A1 (en) 2003-05-22
AU1725201A (en) 2001-07-09
EP1479694A2 (en) 2004-11-24
DE60012980D1 (de) 2004-09-16
JP2013224294A (ja) 2013-10-31
US7258985B2 (en) 2007-08-21
EP1242457B1 (en) 2004-08-11
US20010024831A1 (en) 2001-09-27
DK1242457T3 (da) 2004-12-20
JP2011062205A (ja) 2011-03-31
US20080233110A1 (en) 2008-09-25
ES2225269T3 (es) 2005-03-16
CA2396534C (en) 2012-10-02
CA2396534A1 (en) 2001-07-05
JP2016020388A (ja) 2016-02-04
EP2392596A2 (en) 2011-12-07
AU768827B2 (en) 2004-01-08
EP1479694A3 (en) 2010-05-05
EP2392596A3 (en) 2013-11-27
EP1242457A1 (en) 2002-09-25
EP1479694B1 (en) 2016-10-26
ATE273323T1 (de) 2004-08-15
JP2004504007A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
DE60012980T2 (de) Intrakörper mit definierter struktur ("framework"), die in einer reduzierenden umgebung stabil ist, und ihre verwendungen
DE60013767T2 (de) Verfahren zur herstellung von antikörperfragmenten
DE69130563T2 (de) Screening-verfahren für genbanken (recombinant libraries)
DE69820054T3 (de) Methode zur in vitro molekularen evolution einer proteinfunktion
DE19742706B4 (de) Lipocalinmuteine
DE69131017T2 (de) Optimierung von bindenden proteinen
DE69818458T2 (de) Ribosom-komplexe als selektionspartikel für die in vitro anzeige und evolution von proteinen
EP1566442B1 (de) Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
AT503902B1 (de) Verfahren zur manipulation von immunglobulinen
EP1200583B1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE69621940T2 (de) Protein-/(poly)peptidbibliotheken
DE69526497T2 (de) Dna-mutagenese durch zufallsfragmentierung und wiederaufbau
DE69330523T2 (de) Immunoglobuline ohne leichte ketten
EP1652920B1 (de) Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
JP2004504007A5 (https=)
DE60126482T2 (de) Einkettige antikörper gegen eine p53 mutante
DE69932446T2 (de) Verfahren zur herstellung von nukleinsäure- und polypeptidbanken durch in vivo rekombination und ihre verwendungen
DE60103988T2 (de) Verfahren zur molekularen evolution der antikörperfunktion
EP1307490B1 (de) Fv-konstrukte mit beeinflussbarer affinitat zu einer zu bindenden substanz
DE60316547T2 (de) Doping bei der walk-through-mutagenese
WO2002020614A2 (de) Endoglin spezifisches polypeptid, seine herstellung und verwendung
DE69832622T2 (de) Methoden zur durchforstung (screenen) von proteinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1242457

Country of ref document: EP

Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER,